J. Safra Sarasin Holding’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

J. Safra Sarasin Holding’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,799	Closed	-$1.16M	–	553
2025 Q1	$1.16M	Sell	8,799 -21,765	-71%	-$2.71M	0.02%	293
2024 Q4	$2.55M	Buy	30,564 +2,693	+10%	+$221K	0.04%	198
2024 Q3	$2.04M	Sell	27,871 -3,498	-11%	-$263K	0.04%	209
2024 Q2	$2.15M	Buy	+31,369	New	+$2.18M	0.04%	218

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

J. Safra Sarasin Holding's ITCI Position: Q2 2025 in Review

J. Safra Sarasin Holding sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 8,799 shares — an estimated $1.16M sold.

J. Safra Sarasin Holding first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $2.55M in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

J. Safra Sarasin Holding reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
J. Safra Sarasin Holding sold 8,799 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.16M.
J. Safra Sarasin Holding first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
J. Safra Sarasin Holding's Intra-Cellular Therapies Inc. position peaked at $2.55M in Q4 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2025, filed 21 Jul 2025.